Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:19 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal protein Clear all
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Nov 3, 2026, 1:19 AM EST
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
View directory record Official record
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 3, 2026, 1:19 AM EST
Recruiting Phase 2 Interventional

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06207799
View directory record Official record
Conditions
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions
Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 1Phase 2 Interventional Results available

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

NCT02435901
View directory record Official record
Conditions
Sickle Cell Disease, Beta Thalassemia-Major
Interventions
alemtuzumab (Campath IH), Fludarabine, Melphalan, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Hematopoietic Stem Cell Transplantation
Drug · Biological
Lead sponsor
Northwell Health
Other
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Nov 3, 2026, 1:19 AM EST
Terminated Phase 3 Interventional Results available

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

NCT04815083
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer
Interventions
Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo
Drug · Device
Lead sponsor
SBI ALApharma Canada, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Nov 3, 2026, 1:19 AM EST
Terminated Phase 1 Interventional

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583
View directory record Official record
Conditions
Macrophage Activation Syndrome
Interventions
kineret, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Nov 3, 2026, 1:19 AM EST
Terminated Phase 2 Interventional Results available

Reduced Intensity AlloTransplant For Osteopetrosis

NCT00638820
View directory record Official record
Conditions
Osteopetrosis
Interventions
Stem Cell or Umbilical Cord Blood Transplantation, Campath, Busulfan, Clofarabine, Total Lymphoid Irradiation
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Nov 3, 2026, 1:19 AM EST
Withdrawn Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00006123
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, carmustine, cisplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
2
States / cities
Boston, Massachusetts • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Nov 3, 2026, 1:19 AM EST
Withdrawn Early Phase 1 Interventional

Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422096
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Nov 3, 2026, 1:19 AM EST
Completed No phase listed Observational

Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome

NCT00001973
View directory record Official record
Conditions
Polyostotic Fibrous Dysplasia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00003146
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, melphalan, thiotepa, bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 3, 2026, 1:19 AM EST
Completed Not applicable Interventional

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT00056654
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide acetate
Drug
Lead sponsor
Abbott
Industry
Eligibility
Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
55
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Nov 3, 2026, 1:19 AM EST
Terminated Phase 1 Interventional

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

NCT03878927
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CPX-351, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 2 Interventional Results available

Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery

NCT02103114
View directory record Official record
Conditions
ATIII Deficiency
Interventions
Anti-thrombin III, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
Up to 7 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 2 Interventional

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

NCT00165399
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer
Interventions
Docetaxel, Estramustine, Casodex, Zoladex
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 2 Interventional Results available

Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

NCT06319287
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
PEP (Purified Exosome Product) / TISSEEL
Biological
Lead sponsor
Rion Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Blue Ash, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 4 Interventional

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

NCT00139152
View directory record Official record
Conditions
Lung Disease
Interventions
Placebo, Xolair
Drug
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Omaha, Nebraska • Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Nov 3, 2026, 1:19 AM EST
Active, not recruiting Phase 1 Interventional

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

NCT02023463
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Enzalutamide, Goserelin acetate, Leuprolide acetate, Radiation therapy
Drug · Radiation
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2040
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 2 Interventional

Nesiritide and Vo2 Max in Heart Failure Patients

NCT00240084
View directory record Official record
Conditions
Heart Failure
Interventions
nesiritide (Natrecor(TM))
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Nov 3, 2026, 1:19 AM EST
Completed No phase listed Observational

Patient Registry Study of Berinert® in Normal Clinical Practice

NCT01108848
View directory record Official record
Conditions
Includes: Hereditary Angioedema
Interventions
Berinert® (C1 Esterase Inhibitor)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
34
States / cities
Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Nov 3, 2026, 1:19 AM EST
Recruiting Phase 2 Interventional

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 1 Interventional Results available

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

NCT01258387
View directory record Official record
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Nov 3, 2026, 1:19 AM EST
Completed Phase 3 Interventional Results available

Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

NCT00072384
View directory record Official record
Conditions
Intraocular Retinoblastoma
Interventions
liposomal vincristine sulfate, cryosurgery, laser surgery, carboplatin, etoposide, filgrastim
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
11
States / cities
Arcadia, California • Downey, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Nov 3, 2026, 1:19 AM EST